We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Past and current clinical trials into therapeutic and antiviral treatments for COVID-19, how to take part, and which treatments have proven to be effective.
Information on taking, submitting and processing samples which potentially contain MPXV.
Urgent public health message to all NHS service providers regarding Clade I mpox virus (MPXV) infection.
The background, symptoms, diagnosis and management of mpox virus infections.
This page provides an overview of mpox epidemiology, indicating where there may be a risk of clade I and clade II mpox exposure.
These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.
As with all products, the MHRA will keep its safety under close review.
Urgent public health message advising that clade I mpox no longer meets the criteria of a high consequence infectious disease (HCID).
Public health advice for managing cases of clade II mpox in prisons and other prescribed places of detention.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).